Efeitos do Tabagismo na Saúde e Terapêutica Farmacológica de Primeira Linha na Cessação Tabágica
DOI:
https://doi.org/10.24950/rspmi.911Palavras-chave:
Agonistas Nicotínicos, Benzazepinas, Burpropiona, Cessação Tabágica, Perturbações por Uso de Tabaco, QuinoxalinasResumo
Pelo seu impacto na mortalidade, o tabaco é, presentemente,
a mais potente arma de destruição maciça existente no nosso
planeta. A abordagem do tabagismo é fundamental na prevenção quer primária, quer secundária das patologias por ele
provocadas. Existem atualmente três fármacos considerados
de primeira linha na cessação tabágica (nicotina, bupropiona
e vareniclina), com benefícios conhecidos, devendo, contudo, ser bem avaliados os potenciais riscos da sua utilização
nestes doentes.
Downloads
Referências
The MPOWER package. WHO Report on the Global Tobacco Epidemic. Geneve:WHO;2008.
Ezzati M, Lopez AD. Estimates of global mortality attributable to smokingin 2000. Lancet. 2003;362:847-52.
Warning about the dangers of tobacco. WHO Report on the Global Tobacco Epidemic. Geneve:WHO;2011.
U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, U.S. Department of Health and Human Services, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Bethesda:CDC;2004.
Mota P. Efeitos do tabagismo activo para a saúde. In: Tabagismo - do diagnostico ao tratamento. 2ª ed. Lisboa:Lidel;2010.
Bascom R, Kulle T, Kagey-Sobotka A, Proud D. Upper respiratory
tract environmental tobacco smoke sensitivity. Am Rev Respir Dis. 1991;143:1304-11.
Murin S, Bilello KS, Matthay R. Other smoking-affected pulmonary diseases. Clin Chest Med. 2000;21:121-37.
Bense L, Eklund G, Wiman LG. Smoking and the increased risk of contracting spontaneous pneumothorax. Chest. 1987; 92:1009-12.
Janssen JP et al. Videothoracoscopic appearance of first and recurrent pneumothorax. Chest. 1995;108:330-4.
U.S. Surgeon General: The health consequences of smoking: Chronic obstructive lung disease. Washington: US Department of Health and Human Services; 1984.
Sethi JM, Rochester CL. Smoking and chronic obstructive pulmonary disease. In: Clin Chest Med. 2000;21:67-86.
Auerbach O, Hammond EC, Garfinkel L, Benante C. Relation of smokingand age to emphysema. Whole-lung section study. N Engl J Med.
;286:853-857.
Fletcher C. The natural history of chronic bronchitis and emphysema. London:Oxford University Press;1976.
Tager IB, Weiss ST, Muñoz A, Rosner B, Speizer FE. Longitudinal study of the effects of maternal smoking on pulmonary function in children. N Engl J Med. 1983;309:699-703.
Tager IB1, Segal MR, Speizer FE, Weiss ST. The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis. 1988;138:837-49.
Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev
Respir Dis. 1977;115:195-205.
Myers JL. Respiratory bronchiolitis-associated interstitial lung disease. In: Epler GR, editor. Disease of the bronchioles. New York: Raven Press;1994.p.297-305.
Aubry M-C, Wright JL, Myers JL. The pathology of smoking-related lung diseases. In: Clin Chest Med. 2000;21:11-35.
Von Essen S, West W, Sitorius M, Rennard SI. Complete resolution of roentgenographic changes in a patient with pulmonary histiocytosis X.
Chest. 1990;98:765-767.
Mogulkoc N, Veral A, Bishop PW, Bayindir U, Pickering CA, Egan JJ. Pullmonary Langerhans´ Cell Histiocytosis: Radiologic Resolution Following Smoking Cessation. Chest. 1999;115:1452-5.
Blanc PD, Golden JA, Gamsu G, Aberle DR, Gold WM. Asbestos exposure-cigarette smoking interactions among shipyard workers. JAMA.
;259:370-3.
Saag KG, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39:1711-9.
U.S. Department of Health and Human Services. The health consequences of smoking – 50 years of progress: a report of the Surgeon General. Atlanta: 2014. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
Bonetti OP, Lerman LO, Lerman A. Endothelial d ysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168-175.
Villablanca AC, McDonald JM, Rutledge JC. Smoking and cardiovascular disease. Smoking and pulmonary and cardiovascular diseases. Clin Chest Med. 2000;21:159-72.
Groppelli A, Giorgi DM, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. J Hypertens. 1992;10:495-9.
Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Zampi I, Battistelli M, et al. Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension.J Hypertens. 1995;13:1209-15.
Engelstein ED, Zipes DP. Morte Súbita Cardíaca. In: Hurst’s O Coracao Compendio. 9ª ed. Lisboa: McGraw-Hill; 2000.p. 87.
McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study. Circulation. 2008;117:1216-27.
Martinet Y, Bohadana A. Afecções associadas ao consumo de tabaco. In: O Tabagismo – Da prevenção à abstinência. 2ª ed. Lisboa: Climepsi Editores;2003. p.109-18.
Christen WG, Manson JE, Seddon JM, Glynn RJ, Buring JE, Rosner B, et al. A prospective study of cigarette smoking and risk of cataract in men. JAMA. 1992;268:989-93.
Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA. 1996;276:1141-6.
Tan JS, Wang JJ, Younan C, Cumming RG, Rochtchina E, Mitchell P. Smoking and the long-term incidence of cataract: the Blue Mountains Eye Study. Ophthalmic Epidemiol. 2008;15(3):155-61.
U.S. Department of Health and Human Services (U.S. DHHS). The Health Consequences of Smoking: Cancer. A Report of the Surgeon General.
Washington: US Government Printing Office; 1982. Schuster-Kolbe J, Ludwig H. [Smoking and the risk of cancer]. Wien Med Wochenschr. 1994;144(22-23):540-544.
U.S. Department of Health and Human Services. The Health Benefits of Smoking Cessation. (DHHS publication no. (CDC) 90-8416). Atlanta U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 1990.
Fitzpatrick TM, Blair EA. Upper airway complications of smoking. Smoking and Pulmonary and Cardiovascular Diseases. Clin Chest Med.
;21:147-57.
Kramer IR, El-Lablan N, Lee KW. The clinical features and risk of malignant transformation in sublingual keratosis. Br Dent J. 1978;144:171-80. Benhamou S. [Cancers related to tobacco smoking]. Rev Prat. 1993;43:1214-7.
English DR. The quantification of drug caused morbidity and mortality in Australia, Canberra: Commonwealth Department of Human Services and Health; 1995.
Pelucchi C, La Vecchia C, Negri E, Dal Maso L, Franceschi S. Smoking and other risk factors for bladder cancer in women. Prev Med. 2002;35:114-20.
Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001 ;10:725-31.
Giovannucci E, Martínez ME. Tobacco, colorectal cancer, and adenomas: a review of the evidence. J Natl Cancer Inst. 1996;88:1717-30.
Martínez ME, McPherson RS, Annegers JF, Levin B. Cigarette smoking and alcohol consumption as risk factors for colorectal adenomatous
polyps. J Natl Cancer Inst. 1995;87:274-9.
Pogoda JM, Preston-Martin S, Nichols PW, Ross RK. Smoking and Risk of Acute Myeloid Leukemia: Results from a Los Angeles County Case Control Study. Am J Epidemiol. 2002;155:546-53.
Holm G. Smoking as an additional risk for tooth loss. J Periodontol.1994;65:996-1001.
Marwick C. Intensive smoking cessation efforts cost-effective. JAMA. 1996;276:1291-2.
erby CA, Lapane KL, Hume AL, Babour MM, Carleton RA. Is Cigarette Smoking an Effect Modifier of the Relation between Antihypertensive Therapy and Blood Lipids? Epidemiology. 1997;8:48-54.
Uchimoto S, Tsumura K, Hayashi T, Suematsu C, Endo G, Fujii S, Okada K. Impact of cigarette smoking on the incidence of Type 2 diabetes mellitus in middle-aged Japanese men: the Osaka Health Survey. Diabet Med. 1999;16:951-5.
Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, , et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA. 1991;265:614-7.
Brix TH, Hansen PS, Kyvik KO, Hegedüs L. Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med. 2000;160:661-6.
Utiger RD. Cigarette smoking and the thyroid. N Engl J Med. 1995;333:1001-2.
Prummel MF, Wiersinga WM. Smoking and risk of Graves disease. JAMA. 1993;269:479-82.
Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med. 1998;129:632-5.
Jensen J, Christiansen C, Rodbro P. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med. 1985;313: 973-5.
Johansson C, Mellstrom D. An earlier fracture as a risk factor for new fracture and its association with smoking and menopausal age in women. Maturitas. 1996;24:97-106.
Marsh DR, Shah S, Elliott J, Kurdy N. The Ilizarov method in nonunion, malunion and infection of fractures. J Bone Joint Surg Br. 1997;79:273-9.
Heckman JD, Bolander ME, Bucholz RW, Heppenstall RB, Jupiter JB. Factors that affect fracture healing. Am J Orthop. 1997;26:161-4.
An HS, Silveri CP, Simpson JM, File P, Simmons C, Simeone FA, et al. Comparison of smoking habits between patients with surgically confirmed herniated lumbar and cervical disc disease and controls. J Spinal Disord. 1994;7:369-73.
Boshuizen HC, Verbeek JH, Broersen JP, Weel AN. Do smokers get more back pain? Spine. 1993;18:35-40.
Jones G, White C, Nguyen T, Sambrook P, Kelly P, Eisman J. Cigarette smoking and vertebral body deformity. JAMA. 1995;274:1834-1835.
Hadley MN, Reddy SV. Smoking and the human vertebral column: a review of the impact of cigarette use on vertebral bone metabolism and spinal fusion. Neurosurgery. 1997; 41:116-24.
Smith JB, Fenske NA.Cutaneous manifestations and consequences of smoking.J Am Acad Dermatol. 1996;34:717-24.
Fortes C, Mastroeni S, Leffondré K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141:1580-4.
MacMahon B, Trichopoulos D, Cole P, Brown J. Cigarette smoking and urinary estrogens. N Engl J Med. 1982;307:1062-5.
U.S. Department of Health and Human Services. The Health Consequences of Smoking for Women: A Report of the Surgeon General, 1980.
Washington: Public Health Service, Office of the Assistant Secretary for Health, Office of Smoking and Health; 1980.
Brown S, Vessey M, Stratton I. The influence of method of contraception and cigarette smoking on menstrual patterns. Br J Obstet Gynaecol. 1988;95:905-10.
Fraga CG, Motchnik PA, Wyrobek AJ, Rempel DM, Ames BN. Smoking and low antioxidant levels increase oxidative damage to sperm DNA. Mutat Res. 1996;351:199-203.
Agarwal A, Prabakaran SA, Said TM. Prevention of oxidative stress injury to sperm. J Androl. 2005;26:654-60.
Robbins WA, Elashoff DA, Xun L, Jia J, Li N, Wu G, et al. Effect of lifestyle exposures on sperm aneuploidy. Cytogenet Genome Res.
;111:371-7.
American Psychiatric Association. Practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry. 1996;153:1-31.
Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. Depression and the dynamics of smoking. A national perspective. JAMA. 1990;264:1541-1545.
Chaisson RE. Smoking cessation in patients with HIV. JAMA. 1994;272:564.
Olson PE, Earhart KC, Rossetti RJ, Newton JA, Wallace MR. Smoking and risk of cryptococcosis in patients with AIDS. JAMA. 1997;
:629-30.
Bullen C, Whittaker R, McRobbie H, Fagerström K. A clinical imperative:assisting patients who smoke to reduce their risk of cardiovascular disease. Prev Cardiol. 2007 ;10(2 Suppl 1):5-9.
McEwen A, West R. Smoking cessation activities by general practitioners and practice nurses. Tob Control. 2001;10:27-32.
Revell CC, Schroeder SA. Simplicity matters: using system-level changes to encourage clinician intervention in helping tobacco users quit. Nicotine Tob Res. 2005;7(suppl. 1):S67-S69.
Fiore MC, Jaén CR, Baker TB, Treating Tobacco Use and Dependence: 2008 Update . Washington: US Department of Health and Human Services Public Health Service; 2008.
Conversation with Ove Fernö. Addiction. 1994;89:1215-26.
Infarmed. Resumo das Características do Medicamento [acesso em 24 de novembro de 2014] Disponível em: http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=34251&tipo_doc=rcm.
Infarmed. Resumo das Características do Medicamento [acesso em 24 de novembro de 2014] Disponível em:http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=23759&tipo_doc=rcm.
Infarmed. Resumo das Características do Medicamento [acesso em 24 de novembro de 2014] Disponível em: http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=41317&tipo_doc=rcm.
Infarmed. Resumo das Características do Medicamento [acesso em 24 de novembro de 2014] Disponível em: http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=41185&tipo_doc=rcm.
Infarmed. Resumo das Características do Medicamento [acesso em 24 de novembro de 2014] Disponível em: http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=35911&tipo_doc=rcm.
Infarmed. Resumo das Características do Medicamento [acesso em 24 de novembro de 2014] Disponível em: http://www.infarmed.pt/infomed/Efeitos do Tabag ismo na Saúde e Terapêutica Farmacológica de Primeira Linha na Cessação Tab ágica
download_ficheiro.php?med_id=6069&tipo_doc=rcm.
Infarmed. Resumo das Características do Medicamento [acesso em 24 de novembro de 2014] Disponível em: http://www.infarmed.pt/infomed/download_ficheiro.php?med_id=40268&tipo_doc=rcm.
Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:597.
Murray PR, Bailey W, Daniels K, Bjoruson WM, Kurnov R, Connett J, et al. Safety of nicotine policrilex gum used by 3094 participants in the lung health study. Chest. 1996;109: 438-45.
Joseph A, Norman S, Ferry L, Prochezke A, Westman E, Steel B, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792-8.
Hubbard R, Lewis S, Smith C, Godfrey C, Smeeth L, Farrington P, Britton J, et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control. 2005;14(6):416-421.
Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther. 1998;12:239-44.
Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease: nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med. 1994;154:989-95.
Benowitz N, Gourlay S. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422-31.
Rigotti N. Treatment of tobacco use and dependence. N Engl J Med. 2002;346:506-12.
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). 2000 American Psychiatric Association
Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis. 2003;45:429-41.
Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946-55.
Rigotti NA, Thorndike AN, Regan S, McKool K, Pasternak RC, Chang Y, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. 2006;119:1080-7.
Rigotti NA, Pipe A, Benowitz N, Arteaga C, Garza, D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation. 2010;121;221-9.
Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CAMJ. 2011;(183):1359-1366.
FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease.US Food and Drugs Administration; 2011. [consultado em 10 junho 2013] Disponivel em:http://www.fda.gov/Drugs/DrugSafety/ucm259161.htm
Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012:e7176.
Prochaska J, Hilton J. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.BMJ. 2012:e2856
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
